



June 17, 2024, Monthly Update

Introduction: Several Important New Items:

- Zhittya has been cleared to conduct Medical Research Studies for patients with **Severe No Option Heart Disease** in The Bahamas! These studies are scheduled to start in the coming months and Zhittya is now starting the recruitment of people suffering with **Severe No Option Heart Disease** to participate in those studies.
- Zhittya has obtained regulatory clearance in The Bahamas to conduct our Medical Research Studies for **Parkinson's disease**.
- Zhittya has obtained regulatory clearance to conduct Medical Research Studies in the British Virgin Islands (BVI) to treat **critical limb ischemia**.
- Vika & Sergiy Montano will be in Armenia July 17 – 31, 2024, to give presentations on Zhittya's medicine and to meet with government officials and possible clinics to seek clearance to conduct medical research studies there.
- Investment Opportunity: For those individuals in which a Pre-IPO placement would be suitable, we are seeking to privately place some

common shares before the IPO to fund some special operations which have developed over the last 60 days.

Preface

Today, June 17th, we have just returned from the British Virgin Islands where we processed Cohort #25, bringing our total to over 175 people dosed with FGF-1 intranasally for treating Parkinson's disease. We have seen continued improvements in the majority of test subjects, which is reflected in Vika's section of "Patients' Comments". A lot is going on for Zhittya right now and we are progressing nicely.

#1) Zhittya has begun recruiting for patients with Severe No Option Heart Disease for Medical Research Studies in The Bahamas! These studies are scheduled to start in the coming months.

This is an outstanding moment for Zhittya and, I believe, all humanity in the development of FGF-1 to treat severe heart disease. FGF-1 was first injected into the human heart in 1995 in Fulda, Germany to grow new blood vessels which provided critically needed blood leading to enhanced function in the heart muscle. In 1998, the three-year study results were published in the American Heart Association's peer-reviewed journal, "*Circulation*." It was an "EUREKA" moment in the discovery of treating heart disease, namely, that a natural human molecule, FGF-1, could initiate the natural biological process of regenerating new blood vessels; a process called angiogenesis.

In March 1998, a week after I read that report, I was on a plane to Germany to acquire everything the Germans had regarding FGF-1. I had started working on the floor of the Los Angeles Stock Exchange in 1968. I was in the financial

securities business for 30 years as an Investment Banker, raising capital, taking companies public on to the stock market etc., and more. I left all of that so I could work 100% of my time on what I believe is the most important medical project of the last 100 years — treating heart disease by growing new blood vessels in the heart. I have personally met many of the test subjects. One person I met was unable to walk because her heart pain was so bad. She was what was referred to as a “cardiac cripple.” I saw her the day before she was dosed with FGF-1, and she could not walk. Only 90 days later after she was treated with FGF-1, we walked together around the hospital, with her telling me that her pain was gone, and her heart was functioning wonderfully. I loved that day, when I realized my efforts had helped her and others in that study defer their deaths by many years.

Then as always, I remember almost 17 million people are dying every year of heart disease and we might be able to save millions of those lives with our medicine. I believe every day we are delayed, thousands of people are suffering and dying. I calculated around 47,000 people per day were dying of heart disease and we have the medicine that could save maybe 80% of those people.

IMPORTANT: Heart Disease kills 38% of all adults. That is one out of every 3 people. You who are reading this Update now, probably know many people who have died from heart disease. If you know only 10 people in your life, then heart disease has killed 3 or 4 of them. You have a 38% chance of dying from heart disease. Maybe not now, but maybe it is heart disease that steals your life from you in a few years. As you are reading this keep in mind, it may be FGF-1 that saves you, and extends your life and health 5, 10, or 20 years. Treating heart disease with FGF-1 is a wonderful step forward for everyone's health and

all of humanity.

I have put everything into my task and obligation to deliver this medicine to suffering people — it has become my life's purpose. Our journey with the USA FDA has been a 20-year roller coaster ride. One step forward, one step back. A financial crisis which made everything worse, COVID-19 and more - these were all obstacles we had to overcome. I believe in 2025 we will be back at the USA FDA, with a Phase II application to treat “No Option Heart Patients” (our second time!). If all goes well, then maybe by 2027 or 2028, we may be approved by the USA FDA to treat the over one million Americans who I believe are suffering from “No Option Heart disease.”

The fact that we will be able to begin treating those No Option Heart disease patients in The Bahamas in a few months brings joy to my heart. Zhittya will get great data to support our USA FDA efforts and I hope thousands of people facing death today will have their lives extended by going to The Bahamas and being treated now. This approval to treat No Option Heart patients is the answer to a prayer I have been making every night for 26 years!

Heart disease is the number one cause of death in the world, estimated to be responsible for 38% of all deaths of humans. The World Health Organization (WHO) reported that over 17 million people died in 2022 from heart disease. In 1998, one of my business partners had experienced his second quadruple bypass and afterwards he was still in pain and at risk of death and became what is referred to as a No-Option Heart patient. Being a No-Option Heart patient means a person has known heart disease; however, no treatment exists which can treat their medical issue. Treatments like bypass surgery and balloon angioplasty (with

or without stents) are only applicable to a small percentage of people with known heart disease, those people who have obstruction in their larger blood vessels.

More women die of heart disease than men, a fact overlooked by most everyone. The reason is women most often suffer from what is called small vessel heart disease. Small vessel heart disease is when the smaller blood vessels, capillaries and arterioles are obstructed and experience reduced blood flow, so there is less blood reaching desperate heart muscle cells. I would speculate 85% of all deaths from heart disease are the result of small vessel heart disease. There are no treatments for small vessel heart disease, since modern medicine cannot mechanically fix something that it can barely see.

Every person reading this paper has utilized FGF-1 thousands of times in their lives to initiate the human body's natural regeneration process of growing new blood vessels. For example, when you cut yourself, new skin, new nerves, and even new hair follicles grow because of the FGF-1. Your body automatically starts to produce more FGF-1 to help your body to heal. The human body's ability to regenerate is beyond amazing. You have heard of people surviving a heart attack because they had grown "collateral blood vessels." That is the same thing that FGF-1 has done in the human heart in three human research studies, two in Germany and one in the United States. ABC News did a news story on the Phase I human study that Dr. Jacobs oversaw. Watch this to see the biggest medical breakthrough of the last 100 years (in my opinion).

ABC Clip: https://youtu.be/IPtv_0LWK4k?si=3RCKq2lwYu878rp5

Zhittya is now cleared to conduct medical research studies on heart disease in The Bahamas with our Bahamas medical partner: The Bahamas Heart Centre. It will

take several months to get all the logistics functional, however I hope by Fall 2024 we can be treating No Option Heart Patients and extending their lives as has been done with human patients over 80 times before, with no adverse events related to the medicine observed.

In my mind, no bigger business opportunity exists in the world. As reported, over 17 million people died from heart disease in 2022. I am always amazed when I meet a person who has heart disease and they tell me “My cardiologist is the best in the world and I am receiving the best care, so I am not worried about my heart condition.” I say 85% of people with small vessel disease have a disease for which there is no treatment. I believe it is an “Unmet Medical Need.” How can any rational person say heart disease is well treated when 17 million people are dying from it every year? People come to me and say, “I have stents in my heart, I am fine.” I give them my card and tell them to call me when those stents block up in a few years.

This journey starting from 1998 has been arduous, difficult, and with tolls I could never have imagined. Many times, I would ask why this path has been so difficult? When we could be saving millions of lives with a natural molecule nature has already given us? Why has the path been so difficult? Then I remember my father’s words, “Dan, if the task was easy, God would have given it to someone else. He only uses you for the tough tasks!”

We are cleared in The Bahamas, and we can start to save lives again by treating heart disease. A prayer answered!

If you wish for more information or wish to register for the clinical trials or Medical Research Studies, click here: heart-studies.com

#2) Zhittya has obtained regulatory clearance in The Bahamas to conduct our medical research studies for Parkinson's disease.

It is with great joy to announce we have been cleared in The Bahamas to conduct Medical Research Studies for Parkinson's disease. I believe in a few months we can have our first Medical Research Study test subjects treated in The Bahamas. That will be a second clinic, after the British Virgin Islands, and it will increase our capacity to treat more people. This is great news.

#3) Zhittya has obtained regulatory clearance to conduct medical research studies in the British Virgin Islands (BVI) to treat critical limb ischemia.

I am very pleased to report that Zhittya has received clearance in the British Virgin Islands to conduct Medical Research Studies for critical limb ischemia. Critical limb ischemia is an evil form of peripheral artery disease (PAD). It is estimated that over 2 million Americans suffer with critical limb ischemia, for which there is no successful treatment and often leads to amputation and premature death. Based on animal data we see that similar to injecting FGF-1 into the heart and growing new blood vessels, injecting FGF-1 at the blockage in the legs grows new blood vessels, thereby re-establishing blood perfusion and saving the leg. We are now starting our efforts to identify patients with critical leg ischemia for treatment in the BVI. If you are interested in learning more or registering for the clinical trials or Medical Research Studies click here: cli-studies.com

#4) Armenia: Vika & Sergiy Montano will be in Armenia from July 17 – 31, 2024, to give presentations on Zhittya's medicine and to meet with government officials and possible clinics there to seek clearance to conduct medical research studies.

Zhittya will be sending a team, Vika & Sergiy Montano, to Armenia to explore and hopefully advance discussions about obtaining clearance there to conduct Medical Research Studies for Parkinson's disease. Zhittya is always seeking more clinics and more clearances so we can treat more people who need our medicines and to gather data for our research. We are fortunate to have high level introductions and I hope they are successful in Armenia.

Also, with Vika and Sergiy traveling to Armenia, they will most likely travel through the Arab Gulf nations and may stop there for some important meetings. If you are in the Arab Gulf and wish to meet them on their way through to discuss medicine or business, please let us know.

#5) Investment Opportunity: For those individuals which a Pre-IPO placement would be suitable, we are seeking to privately place some common shares before the IPO to fund some special operations which have developed over the last 60 days.

Our projects are advancing very quickly, including the heart, the brain, the lungs, the legs and more. For those persons who are suitable for an investment in Pre-IPO shares, please contact: Mr. Bart Vossen at: bhvossen.rmena@gmail.com

All our business activities are paid by cash on hand. We do not commit to expenditures unless we have the money already in the bank. We have zero debt and never borrow money. Not owing anyone money means you should be able to survive any storm, as we have demonstrated. We have survived COVID-19 and more, because we treat every penny as our money, and in my case, much of it has been my money.

For everyone who has participated in a long distance run knows the pain and

exhaustion as you approach the final stretch of the race. Everyone in the race is tired, everyone is exhausted, everyone is in pain and yet you have to pull from deep inside yourself, and find new energy, new strength, new commitment, and you have to run the hardest you can to win that race. No one wins a long distance race by being the first to the first turn of the race. You win a race by being first across the line at the end of the race when you bring forth all you have left to win. Zhittya, I believe, is in the final stretch before our IPOs and I want to push the pedal to the metal. If you are interested in learning more, contact Bart and if such an investment is suitable for you, he will work with you.

Upcoming Events

July 10 – 13, 2024: FreedomFest in Las Vegas, Nevada

FreedomFest is one of my favorite events taking place in Las Vegas this year. I know from past FreedomFests that we have many followers who read this Monthly Update and who are already shareholders/investors of ours and who attend the FreedomFest.

I will be giving a main stage presentation:

Friday, July 12th at 9:25 AM on the topic of:

Parkinson's Disease: 150 human research subjects have reversed their disease with FGF-1 treatment.

I will be introducing data and videos of some of our Parkinson's disease test subjects and then extending my talk into our treatment for heart disease, lung disease and other brain disorders. Moreover, I will speak on how we are conducting a small study to prove type-2 diabetes in humans can be reversed by

intranasally administering FGF-1. I will also present a quick case on how the USA FDA is taking away our rights to life, liberty, and our pursuit of happiness by their bureaucratic process to hinder innovation. The FDA denies us our ability to obtain treatments to heal ourselves and extend our health and life.

Friday July 12th at 1:30 PM, Dr. Jacobs will be giving a presentation on:

Heart disease, stroke, Parkinson's disease, diabetes and more: Medical breakthroughs with FGF-1 are happening now!

Every presentation Dr. Jacobs has given at FreedomFest has been standing room only. This one will open your eyes to why we will live longer and healthier than you ever dreamed.

I know many of you have been following us for five years, and you have watched our progress and shared in our delays. Many have been true believers from the start, but many of you have been our doubters, who say to me, every year, "Dan, show me proof and I will help." Dr. Jacobs will show you the proof, and you will be impressed. At the last three FreedomFests, Dr. Jacobs' presentations have been standing room only, so do not miss this one — it will be the best proof ever that Zhittya's medicines can extend your health and life!

If you want more information or wish to attend the FreedomFest go to the direct registration link at: <https://freedomfest.swoogo.com/vegas2024>

If you want to go to their website for additional information, go to <https://www.freedomfest.com>

If you wish to attend, Zhittya has a \$50 discount code for **attendees**: **ZHITTYA50** at checkout!

Vika Montano's Patients' Comments Section: Every month, I receive emails and phone calls from our test subjects. I select a few so you can read what those who have joined our Medical Research Studies are reporting to us.

Patient #1)

Email #1:

Dear Vika,

Overall, I'm doing well. Over the past month I've felt "normal" most of the time.

Many times, I forget to take my meds because I don't feel any symptoms.

My back pain has been the most troubling thing I am dealing with. That just stays bad.

Email #2:

Hi Vika,

I saw my neurologist today and she said I looked great, even better than last time!

Vika's Reply:

Awesome!

It makes me super happy. Maybe you should drop a pill or two, since you are doing better. A lot of our patients are cutting on the quantity of the levodopa pills they are taking, and some are completely off them now. Of course they did it slowly step by step.

Keep me updated please.

With best regards, Vika

Patient #2)

Oh Vika. We are both crying as we read your email. God has been blessing Sue and I in so many ways since we returned home from BVI, primarily in our relationship with our Heavenly Father, with each other and with our friends and family. Sue has experienced a number of noteworthy improvements (such as return of taste and smell, ability to uncurl her left-hand fingers without pain, stronger voice, more energy at times, no longer clearing throat on a regular basis, no longer having minor shakes before falling asleep, some relaxing of facial muscle rigidity which then allows a happier look. However, Sue continues to have severe constipation, bladder control issues, and balance control issues (leading to continued falls all too often). With great hope that extra does will bring positive healing of these three biggies for Sue, we want to thank you so much for sending extra doses. This news was quite timely as Sue recently expressed that she was having a hard time maintaining hope. Your news of this is very encouraging. We don't know how you knew Sue's need, but trust that God put Sue on your heart and you listened and obeyed. For that, we are extremely thankful. This is such a blessing! We continue praying thanks for all you and your team are doing to help end the nightmare of this terrible disease. We are really excited to see what improvements/healing the FGF1 will bring in the next several months.

Thank you again for your generous and wonderful news!!! God bless you and Dan and the entire team.

Patient #3)

Hi Vika,

Quick update, I had a check up with a new neurologist. One of his questions was

to spell the word "WORLD" backwards. I did it so fast he took a double take. He asked if I had been asked to do that before. I have not. I spelled it without even thinking about it. Cognitive ability is doing great!

Best, Courtney

Patient #4)

Dear Ms. Vika,

My name is Bic. I'm sending you the result from my last treatments with FGF-1.

Started out with six days (twice per day). By the third day, I started to breathe about 80% better! I got so excited because for about 15 years I couldn't breathe well! By the fifth day, my stiffness and tremors began to go down, the improvements were also about 80%! With less stiffness, I could swallow better, and fine motor skills improved. I got much better control of my overall body movements.

My sense of smell came back a little.

After six days of dosing, I took three weeks off then back with three days of dosing. At this time, my improvements continued until after the second round of being dosed. After that dose, the breathing improvement decreased from 80% to 50% but holds steady. I need to mention that the breathing improvement helps me speak louder and clearer and I can also sing a little again! The stiffness and tremors improvements also decreased from 80% to about 50% but also still hold.

My blood pressure was swinging wildly from 180–190 systolic down to 85–90 systolic. Had to take medicine daily when it zoomed up. After the 6-day treatment period, the blood pressure has been not swingling so wildly, and am taking the

blood pressure medicine only about 1-2 times a week, when the blood pressure spiked. (It may be that the decreased stiffness lowered the measured blood pressure).

Finally, my constipation control has required only occasional Milk of Magnesia use. In fact, for a while had diarrhea, so had to stop using MOM altogether.

Thank you so much for accepting me as one of your lab rats. This lab rat is very grateful and happy!

Warm wishes,

Bic

Patient #5)

Vika,

I thought I would share this with you.

Joey has had a dramatic decline in number of hallucinations. We have not taken the noon C/L in the last few weeks. So that means he is currently taking 1 1/2 C/L in the morning and at night. I believe the FGF-1 has really been helping.

So, looking forward to seeing more improvements in the future!

Thank you so much for your care and service to us.

God Bless you, Linda

Patient #6)

My dear friend,

I am sure Vika keeps you informed as to how I am doing but I wanted to touch

base with you directly and thank you. Your endless energy and dedication promoting FGF-1 is paying off. At 6.5 months I am noticeably better - more energy, stronger and happier. I still have a long hill to climb but it's no longer daunting.

I am thinking clearer, and my memory has improved significantly! As Vika pointed out to me, I am a professional Lab Rat.

I am so grateful for my opportunity to be a part of finding a cure for Parkinson's.

Regards, Penny

Cross Border Medical Tourism

Cross Border Medical Tourism services is for those people who want to be considered for Zhittya's future clinical trials or its current Medical Research Studies. Cross Border's focus is to fill all available slots in the Medical Research Studies in the British Virgin Islands and The Bahamas, while we wait for other clinics to come online.

Cross Border is working on filling the available slots for the next BVI Medical Research Studies (intranasal FGF-1 for Parkinson's disease) on the following dates:

Cohort #26: July 11 – 16, 2024

Cohort #27: August 19 – 24, 2024

Cohort #28: September 5 – 10, 2024

I am showing Cohorts further out in time since we are filling up faster and have fewer spots each month.

Please contact Sam Cross at Cross Border Medical if you wish to be considered for

the BVI cohorts or slots in The Bahamas. Sam's email address is:

sam.crossbordermedical@gmail.com.


In addition, if you are interested in participating in the brain scan studies which will take place at Washington University in St. Louis, please let Sam know. There are a finite number of slots for the imaging studies. These studies will look at brain blood flow, before and after treatment with FGF-1. There has been no reported pain associated with the MRI scan.

Dr. Jack Jacobs

As Dan mentioned above, 1 out of 3 people in the world will die from heart disease and there is excellent prior data, in both animals and humans, that our FGF-1 drug can reverse this disorder. We have recently been approved in The Bahamas to treat patients with severe heart disease and we are anxious to begin! We believe we have an unparalleled opportunity to finally conquer this beast with our FGF-1 molecule.


In the USA, it is estimated that up to 500,000 subjects suffer from severe coronary artery disease (CAD) for which no medical or surgical options exist, a group which has been referred to as "No-Option Heart patients". The etiology of this disease is shown in the figure below. On the left side of the figure the red arrow points to a blockage in a major coronary artery, which is typically addressed with bypass or stenting procedures. However, on the right, with small vessel disease blocking smaller coronary vessels (three red arrows) there is no possibility of performing a bypass or stenting procedure on these vessels. Growing new blood vessels with FGF-1 is their only hope.

Figure 1: Coronary artery angiogram of a no-option heart patient. On the left the arrow points to a coronary artery that is severely occluded. On the right the three circles and arrows point to completely blocked vessels resulting in ischemic heart muscle.




Results from earlier clinical studies in Germany indicated that injections of FGF-1 into ischemic heart muscle resulted in the growth of a dense network of new blood vessels after 12 weeks as shown in the figure below.

Figure legend: Coronary angiogram in a patient with severe CAD before and 12 weeks after the local administration of human FGF-1 into the ischemic heart wall. A “blush” of new blood vessels can be seen around the site of FGF-1 administration.



In a USA FDA-authorized Phase I clinical trial where FGF-1 was injected into the hearts of no-option heart patients there was statistically significant improvement ($p < 0.05$) in three important clinical parameters that are used to measure the efficacy of these drugs. As shown in the figure below, these analytical tests include from left to right, i) angina class (class 4 angina is the most severe), ii) Seattle angina scores (a second assay of angina pain) and iii) time on the treadmill. The treadmill test is the gold standard efficacy test for this class of patients and is the primary endpoint generally accepted by the FDA for approval of a drug.

Figure legend: Results from a USA Phase I clinical trial in which patients with severe CAD received localized injections of human FGF-1 into their ischemic hearts



In addition, in the previous USA study, pharmacokinetic data was collected which looks at plots of circulating levels of FGF-1 at different time points after drug administration. FGF-1 concentrations reach peak levels very rapidly within minutes of injection and then decrease rapidly within the first hour post-injection. FGF-1 levels reach near pre-treatment baseline concentrations within 12–24 hours. No patients in previous clinical studies demonstrated any detectable FGF-1 specific antibodies at either 6 or 12-weeks post-treatment.


Zhittya's Drug Development Program for Coronary Artery Disease

We plan to administer FGF-1 to the heart using three different procedures including: i) laparoscopy, ii) cardiac injection catheter and iii) mini-thoracotomy surgery.

Laparoscopy

Minimally invasive heart surgery, such as laparoscopy, involves making small incisions in the chest which allows the surgeon to reach the heart by going in between the ribs. There is no cutting through the breastbone, as is done in traditional open-heart surgery. Compared with open-heart surgery, this type of surgery often means less pain and a quicker recovery for patients. The laparoscopy procedure is depicted in the figure below and will be used to inject FGF-1 into areas of ischemic heart muscle.


Laparoscopy Procedure



© MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED.

Cardiac Injection Catheter


Cardiac injection catheters represent another minimally invasive way to obtain access to the wall of the heart. Through a femoral artery catheterization, the catheter can be advanced into the heart chambers where injections can be made through a retractable needle in the tip of the catheter as shown in the figure below. The FGF-1 solution is contained within a syringe which attaches to the handle of the injection catheter.



Mini-thoracotomy

Mini-thoracotomy is a surgical procedure where a small incision is made in between the ribs, as shown in the figure below, allowing access to the outside wall of the heart. This procedure was successfully employed for FGF-1 injections into the heart in previous clinical studies. It should be noted that in previous trials, only two injections of FGF-1 solution were administered: one near the site of the coronary artery blockage and a second in a pre-determined ischemic region of

heart muscle. In Zhittya's planned study, 6-10 injections of FGF-1 will be made into the heart at areas agreed upon by the treating cardiologist and cardiac surgeon.



Conclusion by Dan Montano

Writing this monthly update to you has been very emotional for me. Twenty-six years ago, I left the business world I knew, Investment Banking, for this crazy idea of growing blood vessels in the hearts of millions of sick and suffering people. I knew nothing about biotech except that it is a horrible business model which, in 30 years as an Investment Banker, I had always avoided. I was born in East Los Angeles, California in 1948 to poor parents. Besides everyone in our family working all the time, we always had someone starting a new business: a restaurant, bar, laundromat, construction company, etc. My older brother and I, at ages 3 and 4 respectively, bussed tables, washed dishes, and sometimes cooked the meals at our grandmother's restaurant. When I started on the floor of the Los Angeles Stock Exchange at the ripe old age of 20, no one wanted to hire me, so I worked for free for three months until they saw the profits I made for them. I managed an Initial Public Stock Offering (IPO) when I was 22 and it was a

success, because I worked so hard and made everything happen. I took over 100 companies public on the stock market and I made a lot of money in those 30 years as an Investment Banker.

When I read in the *Wall Street Journal* about medical doctors in Germany biologically growing new blood vessels in the heart to treat the number one cause of death in the world, I knew I had to do it. I knew nothing of medicine or biology. What I did know is I had to do this. Below is a link to the ABC news broadcast showing one of the patients, Constance Donnelly, who was a cardiac cripple and the doctors have given her less than a year to live because her heart was in such bad shape. Watch it and see her heart before and then after the FGF-1 treatment. Listen to her words. I had met her the day before she was dosed and then again 90 days later. I cry every time I watch that ABC News clip, because I know my efforts have helped save her life. This reminds me my life has purpose.

Meet Constance Donnelly: https://youtu.be/IPtv_0LWK4k?si=3RCKq2lwYu878rp5

After that Phase I study, we received permission from the FDA to conduct a Phase II study. Halfway through that Phase II trial, the Great Financial Crisis hit everyone like a hurricane. We struggled, we survived, and we sacrificed because we knew the rewards were saving people's lives. Many great people like Dr. Jacobs and more, all sacrificed much because we understood what winning this long-distance race means: saving millions of lives.

Delay after delay, new rules, changes in animal testing, new methods, other companies' problems and more. These drained our souls, drained our spirits, and drained our pockets. When the darkness was so cold and the nights were so empty, the only light we had was to watch the ABC News clip and see the light at

the end of the tunnel — extending life for millions of people. Clearance to start to treating No Option Heart Patients in The Bahamas is not the finish line of this long race; it is the start of the final stretch of this long race. Like a long-distance cross-country runner our legs are tired, our lungs are burning, and we can see more obstacles ahead of us. However, now we can see the final stretch, we can see the finish line and can already taste the win.

I am so very excited with the idea of treating No Option Heart Patients again and saving lives again in The Bahamas soon. Then we move on to the USA and the rest of the world after that. I am emotional because after 15 years of delays and living hell, we are getting back on track to address the number one cause of death in the world. I am emotional because I can now see the pathway to victory and fulfilling a duty and task entrusted to me. My father was at one time a professional boxer in Los Angeles. He had my brother and I boxing from when we were two years old. I boxed Gold Gloves as a teenager and people would ask my father why does Dan win all his fights? He is skinny, he is blind, he is not strong, so how does he do it? My father's answer was always the same, "Dan knows the secret to winning. It is to be the last guy left standing."

I share this with all of you, because I have seen how FGF-1 can heal the heart, heal the brain, heal the legs, and heal more. I have known for 26 years that FGF-1 is a medical miracle, but what I doubted was me. Could I find a way, could I handle the failures, the crisis, the crooks, the fraudsters and could I handle the pain of delays and overcoming obstacle after obstacle? Treating heart patients now in The Bahamas in my mind means we are in the final stretch and even if I fall, my team will bring it home now.

Every night for 26 years I end my night with one prayer, "Please do not let me fail all these people." I will continue that prayer, until after we have USA FDA approvals and medical insurance treating all those who need our medicines for their heart disease, Parkinson's disease, strokes and more and more.

It is amazing how the burning lungs, the exhausted legs, the tired soul all surge with joy when you realize you are coming into the home stretch, and you find renewed strength in all of your body and soul.

I thank you all for being on this journey with us!

Bless you all!

Dan Montano, CEO

Zhittya Genesis Medicine

1120 North Town Center Drive, Suite #270,

Las Vegas, Nevada 89144

United States of America

zgm.care